Innovations in rare cancers, according to leaders at AbbVie, Precigen and the Rare Cancer Research Foundation
Recent research has revealed that one in five cancers diagnosed in the U.S. is a rare cancer. Despite this alarming statistic, significant challenges remain in diagnosing and treating these diseases, as well as providing access to targeted therapies. Additionally, limited funding and clinical trials hinder the development of innovative solutions for rare cancers.
In a recent panel discussion hosted by MATTER, key industry leaders came together to explore the latest breakthroughs and challenges in rare cancer research. The discussion featured insights from:
- Edrice Simmons, VP of U.S. Oncology at AbbVie
- Phil Tennant, Chief Commercial Officer at Precigen
- Marshall Thompson, President of the Rare Cancer Research Foundation
The conversation, moderated by Steven Collens, CEO of MATTER, covered vital aspects of rare cancer treatment, research advancements and the importance of patient-centered care. Following the main panel, audience members had the opportunity to ask questions, leading to a deeper exploration of issues such as:
- Access to specialized treatments for rare cancers
- The importance of clinical trials and funding for research
- Barriers to accurate diagnosis and personalized therapy
- Innovations in patient care and support systems for rare cancer patients
Watch the full event below to learn more about innovations in rare cancers.
Key Takeaways:
- Tissue donations from patients have been crucial in advancing new cancer cell models and understanding cancer biology.
- Rare cancers include both uncommon cancer types and unusual presentations of more common cancers, expanding the scope of what is considered “rare.”
- Bringing diagnostic models to market involves nuanced communication and additional education, particularly when engaging with diverse stakeholders.
About MATTER
At MATTER, we believe collaboration is the best way to improve healthcare. The MATTER collaborative includes more than 1,000 current and alumni startups from around the world, working together with dozens of hospitals and health systems, universities and industry-leading companies to build the future of healthcare. Together we are accelerating innovation, advancing care and improving lives. For more information, visit matter.health and follow @MATTERhealth.